Abbott has announced the launch of a study of a new repair system for leaky tricuspid heart valves.
The first patient has been enrolled in a clinical study that will assess a minimally invasive clip-based repair system for the treatment of moderate or severe tricuspid regurgitation, a common condition affecting the right side of the heart.
“Abbott has launched a new study of a minimally invasive clip-based repair system for treating moderate or severe tricuspid regurgitation.“
This system is built upon more than a decade of development for Abbott's proven MitraClip technology, which has been shown to predictably and effectively treat mitral regurgitation, a similar disease that impacts the left side of the heart.
Dubbed TRILUMINATE, the new study will evaluate the performance of clip-based technology in approximately 75 symptomatic patients at 25 sites across the US and Europe. The trial is expected to support a future application for European CE Mark approval.
Dr Charles Simonton, chief medical officer and divisional vice-president for global medical affairs at Abbott, said: "We look forward to the results of the trial to determine if this new minimally invasive technology has the potential to benefit people living with tricuspid regurgitation just as predictably."
With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Medical Devices